{
    "nctId": "NCT03238196",
    "briefTitle": "Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer",
    "officialTitle": "A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC)",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 35,
    "primaryOutcomeMeasure": "Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must be able to swallow and retain oral medication\n* Patients must be \u2265 18 years of age\n* Female patients of no childbearing potential must be post-menopausal. Postmenopausal female subjects should be defined prior to protocol enrollment by any of the following:\n* Participants at least 60 years of age; OR\n* Participants under 60 years of age and naturally (spontaneous, no alternative pathologic or physiological cause) amenorrhea for at least 12 months; OR\n* Medical ovarian failure confirmed by follicle-stimulating hormone (FSH) and estradiol levels in the post menopausal range per local institutional normal range; OR\n* Prior bilateral oophorectomy; OR\n* Prior radiation castration with amenorrhea for at least 6 months; OR\n* Treatment with a luteinizing hormone-releasing hormone (LH-RH) agonist (such as goserelin acetate or leuprolide acetate) is permitted for induction of ovarian suppression as long as it has been initiated at least 28 days prior to study enrollment\n* Patients must have ECOG performance status 0 - 1\n* Patients must have clinical stage IV or inoperable locoregional recurrent invasive mammary carcinoma that is:\n* ER+ and/or PgR+ (\u2265 1% positive stained cells) by immunohistochemistry (IHC)\n* HER2-negative (by IHC or FISH, per ASCO guidelines)\n* FGFR1 - 4 amplified\n* Patients must have evaluable (may have either measurable or non-measurable) disease\n* Patients must have available tissue for FGFR determination\n* Patients must have had at least one line of therapy in the metastatic setting\n* Current use of any of the drugs listed on the Cautionary Concomitant Med list has to be approved by the Study Chair\n* Patients must have adequate hematologic, hepatic and renal function. All laboratory tests must be obtained within 2 weeks from study drug initiation. These include:\n* ANC \u2265 1,500/mm3\n* Platelet count \u2265 100,000/mm3\n* HgB \u2265 9.0 g/dL\n* Creatinine clearance \u2265 40 mL/min/1.73 m2\n* SGOT, SGPT \u2264 2.5 x ULN if no liver metastasis present; SGOT, SGPT \u2264 4 x ULN if liver metastasis present\n* Albumin \u2265 2.0 g/dL\n* Total serum bilirubin \u2264 1.5 x ULN (\u2264 3 x ULN or direct bilirubin \u2264 1.5 x ULN if known Gilbert's syndrome)\n* Potassium within institutional normal limits\n* Phosphorus \u2264 institutional upper limit of normal\n\nExclusion Criteria:\n\n* Prior use of an FGFR inhibitor\n* More than 2 lines of chemotherapy in the metastatic setting. No limit on endocrine therapy lines. Prior exposure to CDK4/6 inhibitor acceptable.\n* Radiation therapy \u2264 2 weeks prior to study entry. Patients who have received prior radiotherapy must have recovered from toxicity (\u2264 grade 1) induced by this treatment (except for alopecia)\n* Prior cancer therapy (except for endocrine therapy) must have been discontinued for 1 week prior to initiation of study drugs\n* Concurrent anti-cancer therapy other than the ones specified in the protocol is not permitted during study participation. Bisphosphonates or denosumab are allowed\n* Major surgery within 4 weeks of enrollment\n* Herbal preparations are not allowed throughout the study, and should be discontinued 14 days prior to initiation of study treatment\n* Any corneal or retinal abnormality likely to increase the risk of eye toxicity, such as:\n* Current corneal pathology such as keratitis, keratoconjunctivitis, keratopathy, corneal abrasion, inflammation or ulceration\n* Uncontrolled glaucoma despite standard of care therapy\n* Diabetic retinopathy with macular edema\n* Known active wet, age-related macular degeneration (AMD)\n* Known central serous retinopathy (CSR) or retinal vascular occlusion (RVO)\n* Uncontrolled intercurrent illness including, but not limited to:\n* Malabsorption syndrome significantly affecting gastrointestinal function\n* Ongoing or active infection requiring antibiotics/antivirals\n* Impairment of lung function (COPD \\> grade 2, lung conditions requiring oxygen therapy)\n* Symptomatic congestive heart failure\n* Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months\n* Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment \\[National Cancer Institute -Common Terminology Criteria for Adverse Events, Version 4.03, grade 3\\]\n* QTcF \u2265 480 msec on screening EKG\n* Known history of clinically significant QT/QTc prolongation or Torsades de Pointes(TdP)\n* ST depression or elevation of \u2265 1.5 mm in 2 or more leads\n* Diarrhea of any cause \u2265 CTCAE grade 2 that does not resolve within a few days when adequately treated with anti-diarrhea medications\n* Psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance/pill diary\n* Symptomatic brain metastases (patients with a history of brain metastases must be clinically stable for more than 4 weeks from completion of radiation treatment and be off steroids)\n* Known history of chronic liver or chronic renal failure\n* Poor wound healing capacity",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}